User menu

Historical Perspectives in the Development of Antiviral Agents Against Poxviruses

Bibliographic reference De Clercq, Erik. Historical Perspectives in the Development of Antiviral Agents Against Poxviruses. In: Viruses, Vol. 2, no. 6, p. 1322-1339 (2010)
Permanent URL http://hdl.handle.net/2078.1/34638
  1. Bauer (1972)
  2. Domagk G., Behnisch R., Mietzsch F., Schmidt H. S., Uber eine neue, gegen Tuberkelbazillen in vitro wirksame Verbindungsklasse, 10.1007/bf00624524
  3. Hamre D., Bernstein J., Donovick R., Activity of p-Aminobenzaldehyde, 3-Thiosemicarbazone on Vaccinia Virus in the Chick Embryo and in the Mouse, 10.3181/00379727-73-17652
  4. Hamre, J. Immunol., 67, 305 (1951)
  5. Thompson R. L., Price M. L., Minton S. A., Protection of Mice Against Vaccinia Virus by Administration of Benzaldehyde Thiosemicarbazone., 10.3181/00379727-78-18957
  6. Bauer (1972)
  7. Thompson, J. Immunol., 70, 229 (1953)
  8. Thompson R. L., Davis J., Russell P. B., Hitchings G. H., Effect of Aliphatic Oxime and Isatin Thiosemicarbazones on Vaccinia Infection in the Mouse and in the Rabbit, 10.3181/00379727-84-20690
  9. Bauer, Br. J. Exp. Pathol., 36, 105 (1955)
  10. Bauer D.J., Vincent LeoneSt., Kempe C.Henry, Downie A.W., PROPHYLACTIC TREATMENT OF SMALLPOX CONTACTS WITH N-METHYLISATIN β-THIOSEMICARBAZONE (COMPOUND 33T57, MARBORAN), 10.1016/s0140-6736(63)90230-7
  11. De Clercq, Appl. Microbiol., 16, 1314 (1968)
  12. Boyle, Antimicrob. Agents Chemother., 6, 536 (1966)
  13. Clercq E. D., Luczak M., Shugar D., Torrence P. F., Waters J. A., Witkop B., Effect of Cytosine Arabinoside, lododeoxyuridine, Ethyldeoxyuridine, Thiocyanatodeoxyuridine, and Ribavirin on Tail Lesion Formation in Mice Infected with Vaccinia Virus, 10.3181/00379727-151-39241
  14. De Clercq Erik, Bergstrom Donald E., John Antonin Holy, Montgomery A., Broad-spectrum antiviral activity of adenosine analogues, 10.1016/0166-3542(84)90012-3
  15. Van Aerschot A., Herdewijn P., Janssen G., Cools M., De Clercq E., Synthesis and antiviral activity evaluation of 3′-fluoro-3′-deoxyribonucleosides: broad-spectrum antiviral activity of 3′-fluoro-3′-deoxyadenosine, 10.1016/0166-3542(89)90047-8
  16. De Clercq E, Holy A, Rosenberg I, Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo., 10.1128/aac.33.2.185
  17. De Clercq E, Cools M, Balzarini J, Snoeck R, Andrei G, Hosoya M, Shigeta S, Ueda T, Minakawa N, Matsuda A, Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds., 10.1128/aac.35.4.679
  18. Neyts J., De Clercq E., Efficacy of 2-Amino-7-(1,3-Dihydroxy-2-Propoxymethyl)Purine for Treatment of Vaccinia Virus (Orthopoxvirus) Infections in Mice, 10.1128/aac.45.1.84-87.2001
  19. TIGNOR GREGORY H., KENDE MEIR, HANHAM CATHERINE A., Chemotherapeutic Prevention of Complications Caused by Vaccinia Virus-Vectored Immunogen, 10.1111/j.1749-6632.1992.tb19660.x
  20. Walton Edward, Jenkins Susan R., Nutt Ruth F., Holly Frederick W., Nemes Marjorie, Branched-chain sugar nucleosides. V. Synthesis and antiviral properties of several branched-chain sugar nucleosides, 10.1021/jm00302a025
  21. Tseng Christopher K. H., Marquez Victor E., Fuller Richard W., Goldstein Barry M., Haines David R., McPherson Howard, Parsons Jack L., Shannon William M., Arnett Gussie, Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities, 10.1021/jm00127a007
  22. Smee Donald F, Sidwell Robert W, A review of compounds exhibiting anti-orthopoxvirus activity in animal models, 10.1016/s0166-3542(02)00199-7
  23. Clercq Erik De, Chapter 1 Looking Back in 2009 at the Dawning of Antiviral Therapy Now 50 Years Ago, Advances in Virus Research (2009) ISBN:9780123747860 p.1-53, 10.1016/s0065-3527(09)73001-5
  24. Prusoff William H., Synthesis and biological activities of iododeoxyuridine, an analog of thymidine, 10.1016/0006-3002(59)90597-9
  25. Herrmann E. C., Plaque Inhibition Test for Detection of Specific Inhibitors of DNA Containing Viruses, 10.3181/00379727-107-26560
  26. Kaufman Herbert E., Nesburn Anthony B., Maloney Emily D., Cure of vaccinia infection by 5-iodo-2′-deoxyuridine, 10.1016/0042-6822(62)90058-2
  27. De Clercq E., Vaccinia Virus Inhibitors as a Paradigm for the Chemotherapy of Poxvirus Infections, 10.1128/cmr.14.2.382-397.2001
  28. De Clercq, Meth. Find. Exptl. Clin. Pharmacol., 2, 253 (1980)
  29. De Clercq, Mol. Pharmacol., 14, 422 (1978)
  30. De clercq E., Descamps J., Schmidt C.L., Mertes M.P., Antiviral activity of 5-methylthiomethyl-2′deoxyuridine and other 5-substituted 2′-deoxyuridines, 10.1016/0006-2952(79)90117-5
  31. De Clercq E., Descamps J., Verhelst G., Walker R. T., Jones A. S., Torrence P. F., Shugar D., Comparative Efficacy of Antiherpes Drugs against Different Strains of Herpes Simplex Virus, 10.1093/infdis/141.5.563
  32. Swierkowski M, Shugar D, Notes. A Nonmutagenic Thymidine Analog with Antiviral Activity. 5-Ethyldeoxyuridine, 10.1021/jm00303a617
  33. Nemes M. M., Hilleman M. R., Effective Treatment of Experimental Herpes Simplex Keratitis with New Derivative, 5-Methylamino-2'-Deoxyuridine (MADU), 10.3181/00379727-119-30224
  34. Offit, 1 (2007)
  35. De Clercq, 57 (1985)
  36. Neyts J., Verbeken E., De Clercq E., Effect of 5-Iodo-2'-Deoxyuridine on Vaccinia Virus (Orthopoxvirus) Infections in Mice, 10.1128/aac.46.9.2842-2847.2002
  37. De Clercq E, Antiviral and antimetabolic activities of neplanocins., 10.1128/aac.28.1.84
  38. De Clercq E, Cools M, Balzarini J, Marquez V E, Borcherding D R, Borchardt R T, Drach J C, Kitaoka S, Konno T, Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5'-nor derivatives., 10.1128/aac.33.8.1291
  39. Hasobe M, McKee J G, Borcherding D R, Borchardt R T, 9-(trans-2',trans-3'-Dihydroxycyclopent-4'-enyl)-adenine and -3-deazaadenine: analogs of neplanocin A which retain potent antiviral activity but exhibit reduced cytotoxicity., 10.1128/aac.31.11.1849
  40. Hasobe, Antiviral Chem. Chemother., 4, 245 (1993)
  41. Cools, Mol. Pharmacol., 39, 718 (1991)
  42. Patil Sharadbala D., Schneller Stewart W., Hosoya Mitsuaki, Snoeck Robert, Andrei Graciela, Balzarini Jan, De Clercq Erik, The synthesis and antiviral properties of (.+-.)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design, 10.1021/jm00096a012
  43. Siddiqi Suhaib M., Chen Xing, Schneller Stewart W., Ikeda Satoru, Snoeck Robert, Andrei Graciela, Balzarini Jan, De Clercq Erik, Antiviral Enantiomeric Preference for 5'-Noraristeromycin, 10.1021/jm00030a014
  44. Siddiqi Suhaib M., Chen Xing, Schneller Stewart W., Ikeda Satoru, Snoeck Robert, Andrei Graciela, Balzarini Jan, De Clercq Erik, An Epimer of 5'-Noraristeromycin and Its Antiviral Properties, 10.1021/jm00035a020
  45. Siddiqi Suhaib M., Chen Xing, Rao Jagadishwar, Schneller Stewart W., Ikeda Satoru, Snoeck Robert, Andrei Graciela, Balzarini Jan, De Clercq Erik, 3-Deaza- and 7-Deaza-5'-noraristeromycin and Their Antiviral Properties, 10.1021/jm00006a023
  46. Shuto Satoshi, Obara Takumi, Toriya Minoru, Hosoya Mitsuaki, Snoeck Robert, Andrei Graciela, Balzarini Jan, De Clercq Erik, New neplanocin analogs. 1. Synthesis of 6'-modified neplanocin A derivatives as broad-spectrum antiviral agents, 10.1021/jm00080a018
  47. Shuto Satoshi, Obara Takumi, Saito Yasuyoshi, Andrei Graciela, Snoeck Robert, De Clercq Erik, Matsuda Akira, New Neplanocin Analogues. 6. Synthesis and Potent Antiviral Activity of 6‘-Homoneplanocin A1, 10.1021/jm950853f
  48. Obara Takumi, Shuto Satoshi, Saito Yasuyoshi, Snoeck Robert, Andrei Graciela, Balzarini Jan, De Clercq Erik, Matsuda Akira, New Neplanocin Analogues. 7. Synthesis and Antiviral Activity of 2-Halo Derivatives of Neplanocin A1, 10.1021/jm960145+
  49. de Clercq Erik, Murase Junichi, Marquez Victor E., Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase, 10.1016/0006-2952(91)90120-t
  50. Marquez Victor E., Lim Mu Ill, Treanor Susan P., Plowman Jacqueline, Priest Matthew A., Markovac Anica, Khan M. Sami, Kaskar Bashir, Driscoll John S., Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties, 10.1021/jm00117a004
  51. Van Aerschot Arthur A., Mamos Petros, Weyns Nancy J., Ikeda Satoru, De Clercq Erik, Herdewijn Piet A., Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents, 10.1021/jm00072a013
  52. Neyts J, Andrei G, Snoeck R, Jahne G, Winkler I, Helsberg M, Balzarini J, De Clercq E, The N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine is a potent and selective inhibitor of herpesvirus replication., 10.1128/aac.38.12.2710
  53. Neyts, Mol. Pharmacol., 53, 157 (1998)
  54. Whitley Richard J., Ch'ien Lawrence T., Dolin Raphael, Galasso George J., Alford Charles A., , Adenine Arabinoside Therapy of Herpes Zoster in the Immunosuppressed : NIAID Collaborative Antiviral Study, 10.1056/nejm197605272942201
  55. De Clercq Erik, Another ten stories in antiviral drug discovery (part C): “Old” and “new” antivirals, strategies, and perspectives, 10.1002/med.20153
  56. Rada Břetislav, Dragúň Marián, ANTIVIRAL ACTION AND SELECTIVITY OF 6-AZAURIDINE, 10.1111/j.1749-6632.1977.tb21977.x
  57. Rada B., Blaškovič D., Šorm F., Škoda J., The inhibitory effect of 6-azauracil riboside on the multiplication of vaccinia virus, 10.1007/bf02158350
  58. Clercq Erik De, Holý Antonin, Rosenberg Ivan, Sakuma Takashi, Balzarini Jan, Maudgal Parbhat C., A novel selective broad-spectrum anti-DNA virus agent, 10.1038/323464a0
  59. Clercq Erik De, Sakuma Takashi, Baba Masanori, Pauwels Rudi, Balzarini Jan, Rosenberg Ivan, Holý Antonin, Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines, 10.1016/s0166-3542(87)80004-9
  60. De Clercq E., Therapeutic potential of HPMPC as an antiviral drug, 10.1002/rmv.1980030205
  61. De Clercq E, Holy A, Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice., 10.1128/aac.35.4.701
  62. Neyts Johan, Clercq Erik De, Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice, 10.1002/jmv.1890410312
  63. Henderson D.A., Bioterrorism as a Public Health Threat, 10.3201/eid0403.980340
  64. Breman Joel G., Henderson D.A., Poxvirus Dilemmas — Monkeypox, Smallpox, and Biologic Terrorism, 10.1056/nejm199808203390811
  65. Bray Mike, Martinez Mark, Smee Donald F., Kefauver Debbie, Thompson Elizabeth, Huggins John W., Cidofovir Protects Mice against Lethal Aerosol or Intranasal Cowpox Virus Challenge, 10.1086/315190
  66. SMEE D, BAILEY K, WONG M, SIDWELL R, Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir, 10.1016/s0166-3542(00)00105-4
  67. Smee Donald F., Bailey Kevin W., Wong Min-Hui, Sidwell Robert W., Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice, 10.1016/s0166-3542(01)00159-0
  68. Smee, Antiviral Chem. Chemother., 12, 71 (2001)
  69. Bray Mike, Martinez Mark, Kefauver Deborah, West Michael, Roy Chad, Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir, 10.1016/s0166-3542(01)00220-0
  70. ROBBINS S, JACKSON R, FENNER F, BEATON S, MEDVECZKY J, RAMSHAW I, RAMSAY A, The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4, 10.1016/j.antiviral.2004.12.003
  71. De Clercq Erik, Cidofovir in the treatment of poxvirus infections, 10.1016/s0166-3542(02)00008-6
  72. Neyts J., Leyssen P., Verbeken E., De Clercq E., Efficacy of Cidofovir in a Murine Model of Disseminated Progressive Vaccinia, 10.1128/aac.48.6.2267-2273.2004
  73. De Clercq Erik, Neyts Johan, Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections, 10.1002/rmv.439
  74. Geerinck K., Lukito G., Snoeck R., De Vos R., De Clercq E., Vanrenterghem Y., Degreef H., Maes B., A case of human Orf in an immunocompromised patient treated successfully with cidofovir cream, 10.1002/jmv.1084
  75. Fery-Blanco C., Pelletier F., Humbert P., Aubin F., Molluscum contagiosum profus au cours d’une dermatite atopique traitée par tacrolimus : intérêt du cidofovir, 10.1016/s0151-9638(07)89213-1
  76. Clercq Erik De, Holý Antonín, Case history: Acyclic nucleoside phosphonates: a key class of antiviral drugs, 10.1038/nrd1877
  77. Hostetler Karl Y., Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art, 10.1016/j.antiviral.2009.01.005
  78. Painter George R., Hostetler Karl Y., Design and development of oral drugs for the prophylaxis and treatment of smallpox infection, 10.1016/j.tibtech.2004.06.008
  79. Ciesla Stephanie L, Trahan Julissa, Wan W.Brad, Beadle James R, Aldern Kathy A, Painter George R, Hostetler Karl Y, Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney, 10.1016/s0166-3542(03)00110-4
  80. Aldern K. A., Increased Antiviral Activity of 1-O-Hexadecyloxypropyl-[2-14C]cidofovir in MRC-5 Human Lung Fibroblasts Is Explained by Unique Cellular Uptake and Metabolism, 10.1124/mol.63.3.678
  81. Kern E. R., Hartline C., Harden E., Keith K., Rodriguez N., Beadle J. R., Hostetler K. Y., Enhanced Inhibition of Orthopoxvirus Replication In Vitro by Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir, 10.1128/aac.46.4.991-995.2002
  82. Keith K. A., Wan W. B., Ciesla S. L., Beadle J. R., Hostetler K. Y., Kern E. R., Inhibitory Activity of Alkoxyalkyl and Alkyl Esters of Cidofovir and Cyclic Cidofovir against Orthopoxvirus Replication In Vitro, 10.1128/aac.48.5.1869-1871.2004
  83. Quenelle D. C., Collins D. J., Wan W. B., Beadle J. R., Hostetler K. Y., Kern E. R., Oral Treatment of Cowpox and Vaccinia Virus Infections in Mice with Ether Lipid Esters of Cidofovir, 10.1128/aac.48.2.404-412.2004
  84. Buller R.Mark, Owens Gelita, Schriewer Jill, Melman Lora, Beadle James R, Hostetler Karl Y, Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model, 10.1016/j.virol.2003.11.015
  85. Beadle James R., Wan William B., Ciesla Stephanie L., Keith Kathy A., Hartline Caroll, Kern Earl R., Hostetler Karl Y., Synthesis and Antiviral Evaluation of Alkoxyalkyl Derivatives of 9-(S)-(3-Hydroxy-2-phosphonomethoxypropyl)adenine against Cytomegalovirus and Orthopoxviruses, 10.1021/jm050473m
  86. Quenelle D. C., Collins D. J., Herrod B. P., Keith K. A., Trahan J., Beadle J. R., Hostetler K. Y., Kern E. R., Effect of Oral Treatment with Hexadecyloxypropyl-[(S)-9-(3-Hydroxy-2- Phosphonylmethoxypropyl)Adenine] [(S)-HPMPA] or Octadecyloxyethyl-(S)-HPMPA on Cowpox or Vaccinia Virus Infections in Mice, 10.1128/aac.00184-07
  87. Byrd C. M., Bolken T. C., Mjalli A. M., Arimilli M. N., Andrews R. C., Rothlein R., Andrea T., Rao M., Owens K. L., Hruby D. E., New Class of Orthopoxvirus Antiviral Drugs That Block Viral Maturation, 10.1128/jvi.78.22.12147-12156.2004
  88. Byrd C. M., Bolken T. C., Hruby D. E., Molecular Dissection of the Vaccinia Virus I7L Core Protein Proteinase, 10.1128/jvi.77.20.11279-11283.2003
  89. Byrd C. M., Bolken T. C., Hruby D. E., The Vaccinia Virus I7L Gene Product Is The Core Protein Proteinase, 10.1128/jvi.76.17.8973-8976.2002
  90. Yang G., Pevear D. C., Davies M. H., Collett M. S., Bailey T., Rippen S., Barone L., Burns C., Rhodes G., Tohan S., Huggins J. W., Baker R. O., Buller R. L. M., Touchette E., Waller K., Schriewer J., Neyts J., DeClercq E., Jones K., Hruby D., Jordan R., An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge, 10.1128/jvi.79.20.13139-13149.2005
  91. Husain Matloob, Weisberg Andrea, Moss Bernard, Topology of epitope-tagged F13L protein, a major membrane component of extracellular vaccinia virions, 10.1016/s0042-6822(03)00063-1
  92. Bailey Thomas R., Rippin Susan R., Opsitnick Elizabeth, Burns Christopher J., Pevear Daniel C., Collett Marc S., Rhodes Gerry, Tohan Sanjeev, Huggins John W., Baker Robert O., Kern Earl R., Keith Kathy A., Dai Dongcheng, Yang Guang, Hruby Dennis, Jordan Robert, N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides:  Identification of Novel Orthopoxvirus Egress Inhibitors, 10.1021/jm061484y
  93. Duraffour, Antivir. Ther., 12, 1205 (2007)
  94. Quenelle D. C., Buller R. M. L., Parker S., Keith K. A., Hruby D. E., Jordan R., Kern E. R., Efficacy of Delayed Treatment with ST-246 Given Orally against Systemic Orthopoxvirus Infections in Mice, 10.1128/aac.00879-06
  95. Sbrana, Am. J. Trop. Med. Hyg., 76, 768 (2007)
  96. Nalca Aysegul, Hatkin Josh M., Garza Nicole L., Nichols Donald K., Norris Sarah W., Hruby Dennis E., Jordan Robert, Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model, 10.1016/j.antiviral.2008.03.005
  97. Quenelle D. C., Prichard M. N., Keith K. A., Hruby D. E., Jordan R., Painter G. R., Robertson A., Kern E. R., Synergistic Efficacy of the Combination of ST-246 with CMX001 against Orthopoxviruses, 10.1128/aac.00762-07
  98. Vora Surabhi, Damon Inger, Fulginiti Vincent, Weber Stephen G., Kahana Madelyn, Stein Sarah L., Gerber Susan I., Garcia‐Houchins Sylvia, Lederman Edith, Hruby Dennis, Collins Limone, Scott Dorothy, Thompson Kenneth, Barson John V., Regnery Russell, Hughes Christine, Daum Robert S., Li Yu, Zhao Hui, Smith Scott, Braden Zach, Karem Kevin, Olson Victoria, Davidson Whitni, Trindade Giliane, Bolken Tove, Jordan Robert, Tien Debbie, Marcinak John, Severe Eczema Vaccinatum in a Household Contact of a Smallpox Vaccinee, 10.1086/587668
  99. Huggins J., Goff A., Hensley L., Mucker E., Shamblin J., Wlazlowski C., Johnson W., Chapman J., Larsen T., Twenhafel N., Karem K., Damon I. K., Byrd C. M., Bolken T. C., Jordan R., Hruby D., Nonhuman Primates Are Protected from Smallpox Virus or Monkeypox Virus Challenges by the Antiviral Drug ST-246, 10.1128/aac.00021-09
  100. Duraffour, Drugs, 13, 181 (2010)
  101. Snoeck (2007)
  102. Yang Hailin, Kim Sung-Kwon, Kim Mikyung, Reche Pedro A., Morehead Tiara J., Damon Inger K., Welsh Raymond M., Reinherz Ellis L., Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction, 10.1172/jci200523220
  103. Reeves Patrick M, Bommarius Bettina, Lebeis Sarah, McNulty Shannon, Christensen Jens, Swimm Alyson, Chahroudi Ann, Chavan Rahul, Feinberg Mark B, Veach Darren, Bornmann William, Sherman Melanie, Kalman Daniel, Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases, 10.1038/nm1265
  104. McFadden Grant, Gleevec casts a pox on poxviruses, 10.1038/nm0705-711
  105. Gubser, J. Gen. Virol., 83, 855 (2002)
  106. Smee D. F., Sidwell R. W., Kefauver D., Bray M., Huggins J. W., Characterization of Wild-Type and Cidofovir-Resistant Strains of Camelpox, Cowpox, Monkeypox, and Vaccinia Viruses, 10.1128/aac.46.5.1329-1335.2002
  107. Duraffour S., Snoeck R., Krecmerova M., van Den Oord J., De Vos R., Holy A., Crance J.-M., Garin D., De Clercq E., Andrei G., Activities of Several Classes of Acyclic Nucleoside Phosphonates against Camelpox Virus Replication in Different Cell Culture Models, 10.1128/aac.00838-07
  108. Duraffour, Antivir. Ther., 13, 977 (2008)
  109. Stittelaar Koert J., Neyts Johan, Naesens Lieve, van Amerongen Geert, van Lavieren Rob F., Holý Antonin, De Clercq Erik, Niesters Hubert G. M., Fries Edwin, Maas Chantal, Mulder Paul G. H., van der Zeijst Ben A. M., Osterhaus Albert D. M. E., Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection, 10.1038/nature04295